IN BRIEF: Syncona's portfolio Achilles Therapeutics net loss narrows
Syncona Ltd - Healthcare company focused on developing its life science portfolio - Notes its portfolio company Archilles Therapeutics PLC's net loss in its second quarter ended June 30 narrows 2.9% to USD16.8 million, from USD17.3 million year-on-year. Cash and cash equivalents are "strong", standing at USD143.7 million on June 30, down 17% from USD173.3 million on December 31. Research & development expenses increase are USD13.8 million, down 6.8% from USD14.8 million at the same point the year prior. Archilles Therapeutics's general & administrative expenses were USD4.3 million, down 26% from USD5.8 million the year before, driven by a change in cost allocations and lower professional fees.
Read more